CD4 and cancer: If the antigenic peptide comes from a transformed or cancer cell, this partially activated CD4+ T cell after leaving the thymus likely will further encounter the same MHC-II-complexed antigen in the periphery, and thus its activation by this antigen will be further confirmed.